GlassScriptPhysician profile
Julia A Kovacs
NPI 1366527798
$4,251.11
in general payments reported to CMS, 2019-2025
34 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.71 · 2020: $76.91 · 2021: $573 · 2022: $577 · 2023: $893 · 2024: $1,076 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,011.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $568.09 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $534.73 | 2021-2025 | |
| Novo Nordisk INC | $441.22 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $417.06 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $393.94 | 2021-2024 | |
| Viiv Healthcare Company | $384.72 | 2021-2025 | Apretude, Dovato |
| Amgen INC. | $166.13 | 2021-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $141.61 | 2021-2025 | |
| Glaxosmithkline, LLC. | $137.14 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.48 | 2020-2025 | Jardiance |
| Dexcom, INC. | $95.32 | 2021-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $76.47 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.93 | 2020-2025 | Xifaxan |
| Biosense Webster, INC. | $64.52 | 2021 | |
| Abbott Laboratories | $63.20 | 2022-2023 | Freestyle Libre 3 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $60.49 | 2022-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $57.74 | 2021-2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $42.58 | 2022 | |
| Azurity Pharmaceuticals, INC. | $41.90 | 2025 | Azmiro |
| Merck Sharp & Dohme LLC | $40.02 | 2020-2021 | |
| Astellas Pharma US INC | $39.86 | 2021-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $38.02 | 2023-2025 | |
| Antares Pharma, INC. | $36.42 | 2019-2022 | |
| Baxter Healthcare | $35.77 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Tolmar, INC. | $34.14 | 2025 | Jatenzo |
| Esperion Therapeutics, INC. | $29.86 | 2024-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $22.16 | 2024 | Rexulti |
| Sanofi Pasteur INC. | $21.84 | 2022 | |
| Amarin Pharma, INC. | $20.19 | 2022 | |
| Edwards Lifesciences Corporation | $18.11 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.38 | 2021 | |
| Halozyme INC | $15.74 | 2023 | |
| Genentech USA, INC. | $14.93 | 2020 | |
| Nestle Healthcare Nutrition INC. | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Kovacs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.